Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
02/2010
02/23/2010USRE41151 Comprising a modified NSAID, wherein the NSAID is covalently attached either directly or through a linker molecule to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety; nonsteroidal anti-inflammatory drugs; side-effect reduction
02/23/2010US7667053 Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders
02/23/2010US7667040 Azacyclic ethynyl derivatives
02/23/2010US7667008 Heparin binding protein for use in controlling angiogenesis and as wound healing agent
02/23/2010US7666892 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12
02/23/2010US7666881 4-(4-(4-(Hydroxydiphenylmethyl)-1-piperidinyl)-1-hydroxybutyl)-alpha,alpha -dimethylbenzene acetic acid hydrochloride formed by azeotropic distillation
02/23/2010US7666848 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics
02/23/2010US7666647 Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease
02/23/2010US7666422 Methods for the treatment of cancer using anti-CD40 antibodies
02/23/2010US7666418 Method for treating Th2-mediated disease
02/23/2010CA2433021C Isoindole-imide compounds, compositions, and uses thereof
02/23/2010CA2389743C Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
02/23/2010CA2353448C Improvements in or relating to powders
02/23/2010CA2339049C Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors
02/23/2010CA2303390C Lkta deletion mutant of p. haemolytica
02/18/2010WO2010019646A1 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof
02/18/2010WO2010019099A1 2-hydroxy-ethanesulfonate salt
02/18/2010WO2010019098A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist
02/18/2010WO2010019097A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient
02/18/2010WO2010018461A2 Compositions comprising lactobacillus casei for improving resistance to common infectious diseases
02/18/2010WO2010018352A1 Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
02/18/2010WO2010018329A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
02/18/2010WO2010018328A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
02/18/2010WO2010018113A2 Bi-aryl aminotetralines
02/18/2010WO2010018112A2 Monoaryl aminotetralines
02/18/2010WO2010018109A2 Substituted aminotetralines
02/18/2010WO2010017598A1 Anti-il-12/il-23 antibodies
02/18/2010WO2009157016A3 Compositions comprising extracts from boswellia serrata
02/18/2010WO2009150137A3 Pyrazine derivatives as epithelial sodium channel blockers
02/18/2010WO2009137087A3 A method for preventing or alleviating the noxious effects resulting from toxicant exposure
02/18/2010WO2009126606A3 Regression of established atherosclerotic plaques, and treating sudden-onset asthma attacks, using parp inhibitors
02/18/2010WO2009076602A8 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors
02/18/2010US20100041887 Quinuclidine derivatives binding to mucarinic m3 receptors
02/18/2010US20100041766 Medthods, Devices And Formulations For Targeted Endobronchial Therapy
02/18/2010US20100041735 Modulation of toll-like receptor 3 expression by antisense oligonucleotides
02/18/2010US20100041699 Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid
02/18/2010US20100041685 Stat3 inhibitors
02/18/2010US20100041651 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
02/18/2010US20100041645 Rho kinase inhibitors
02/18/2010US20100041638 Chemical Compounds 293
02/18/2010US20100040714 Asthma/Allergy Therapy that Targets T-lymphoctyes and/or Eosinophils
02/18/2010US20100040712 Throat spray
02/18/2010US20100040691 Pharmaceutical compositions comprising methotrexate
02/18/2010US20100040613 Polypeptide constructs for sublingual administration
02/18/2010US20100040604 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
02/18/2010US20100040538 Polymer Systems for Lung Volume Reduction Therapy
02/18/2010CA2735392A1 Bi-aryl aminotetralines
02/18/2010CA2734327A1 Compositions comprising lactobacillus casei for improving resistance to common infectious diseases
02/18/2010CA2734104A1 Substituted aminotetralines
02/18/2010CA2734082A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
02/18/2010CA2733970A1 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof
02/18/2010CA2733642A1 Anti-il-12/il-23 antibodies
02/18/2010CA2733523A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a .beta.2-adrenoceptor agonist
02/18/2010CA2733449A1 2-hydroxy-ethanesulfonate salt
02/18/2010CA2733447A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient
02/18/2010CA2733397A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
02/18/2010CA2732210A1 Monoaryl aminotetralines
02/17/2010EP2154136A1 Quinuclidine carbonate derivatives and medicinal compositions thereof
02/17/2010EP2154131A1 G protein-coupled receptor inhibitor and pharmaceutical product
02/17/2010EP2153837A1 Compositions comprising Lactobacillus casei for improving resistance to common infectious diseases
02/17/2010EP2153736A1 Novel leukotriene receptor antagonist
02/17/2010EP2152709A1 Morphinan compounds
02/17/2010EP2152679A1 Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions
02/17/2010EP2152674A1 Benzimidazolone chymase inhibitors
02/17/2010EP2152288A1 Reconstituted surfactants having improved properties
02/17/2010EP2152276A1 Screening assay to identify correctors of protein trafficking defects
02/17/2010EP1922074B1 A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma.
02/17/2010EP1511737B1 Aryloximes
02/17/2010CN100589839C Polypeptide and medicament composition containing polypeptide
02/17/2010CN100589806C Use of steroid derivatives for the treatment of angiotensin II related disease e.g. cardiovascular and proliferative disorders
02/16/2010US7662845 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
02/16/2010US7662843 Isoxazoline compounds having MIF antagonist activity
02/16/2010US7662835 Methods of treating allergic reactions using an anhydrous form of antihistaminic piperidine derivatives
02/16/2010US7662826 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
02/16/2010US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma
02/16/2010US7662814 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases
02/16/2010US7662794 DNA enzyme to inhibit plasminogen activator inhibitor-1
02/16/2010US7662633 Method of screening for inhibitors of osteopontin
02/16/2010US7662391 Polynucleotide sequence for Chalmydia pneumonia; therapy, prevention of Chlamydia infections ; vaccines
02/16/2010US7662181 Methods and devices for use in performing pulmonary procedures
02/16/2010CA2478183C Substituted amides
02/16/2010CA2450922C Piperidines for use as orexin receptor antagonists
02/16/2010CA2429109C Anti-inflammatory agents
02/16/2010CA2405531C Microencapsulated fragrances and methods of coating microcapsules
02/16/2010CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
02/16/2010CA2309154C Substituted porphyrins
02/11/2010WO2010017154A2 Modulation of toll-like receptor 3 expression by antisense oligonucleotides
02/11/2010WO2010015870A1 Use of dihydralazine for the treatment of diseases related to elevated semicarbazide sensitive amine-oxidase (ssao) activity
02/11/2010WO2010015818A1 Respiratory disease treatment
02/11/2010WO2010015792A1 Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
02/11/2010WO2010015586A2 2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds
02/11/2010WO2010015585A1 6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds
02/11/2010WO2010015520A1 Substituted naphthyridines and use thereof as medicines
02/11/2010WO2010015518A2 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
02/11/2010WO2010015324A1 Quinuclidine carbonate derivatives and medicinal composition thereof
02/11/2010WO2010015253A1 Pharmaceutical composition for nasal application
02/11/2010WO2009157858A8 Use of cyclolignans for the treatment of a hyperactive immune system
02/11/2010US20100035998 Combination s-nitrosothiol pharmaceutical products for restoring normal breathing rhythms
02/11/2010US20100035954 Acid addition salts of muscarinic receptor antagonists
02/11/2010US20100035943 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
1 ... 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 ... 878